Patents by Inventor Bernard L. Hirschbein
Bernard L. Hirschbein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140256743Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.Type: ApplicationFiled: May 20, 2014Publication date: September 11, 2014Applicants: Merck Frosst Canada Ltd., Axys Pharmaceuticals, Inc.Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra I. Baskaran
-
Patent number: 8772336Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.Type: GrantFiled: October 11, 2012Date of Patent: July 8, 2014Assignees: Merck Frosst Canada Ltd., Axys Pharmaceuticals, Inc.Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra I. Baskaran
-
Patent number: 8318748Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.Type: GrantFiled: May 25, 2011Date of Patent: November 27, 2012Assignees: Merck, Sharp & Dohme Corp., Axys Pharmaceuticals, Inc.Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra Baskaran
-
Publication number: 20110230446Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.Type: ApplicationFiled: May 25, 2011Publication date: September 22, 2011Applicants: Axys Pharmaceuticals, Inc., Merck Canada Inc.Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Chirstophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra Baskaran
-
Patent number: 7973037Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.Type: GrantFiled: April 8, 2008Date of Patent: July 5, 2011Assignees: Axys Pharmaceuticals, Inc., Merck Canada Inc.Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra Baskaran
-
Publication number: 20080188529Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.Type: ApplicationFiled: April 8, 2008Publication date: August 7, 2008Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra Baskaran
-
Publication number: 20030232863Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.Type: ApplicationFiled: February 28, 2003Publication date: December 18, 2003Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra Baskaran
-
Patent number: 5859233Abstract: The invention provides a method of synthesizing oligonucleotide N3'.fwdarw.P5' phosphoramidates using an amine-exchange reaction of phosphoramidites in which a -deprotected 3'-amino group of a solid phase supported oligonucleotide chain is exhanged for the amino portion of a 5'-phosphoramidite of an incoming monomer which has a protected 3'-amino group. The resulting internucleotide phosphoramidite linkage is then oxidized to form a stable protected phosphoramidate linkage. The method of the invention greatly improves product yields and reduces reagent usage over currently available methods for synthesizing the above class of compound.Type: GrantFiled: December 20, 1996Date of Patent: January 12, 1999Assignee: Lynx Therapeutics, Inc.Inventors: Bernard L. Hirschbein, Karen L. Fearon, Sergei M. Gryaznov, Sarah N. McCurdy, Jeffrey S. Nelson, Ronald G. Schultz
-
Patent number: 5824793Abstract: The invention provides a method of synthesizing oligonucleotide N3'.fwdarw.P5' phosphoramidates using an amine-exchange reaction of phosphoramidites in which a deprotected 3'-amino group of a solid phase supported oligonucleotide chain is exhanged for the amino portion of a 5'-phosphoramidite of an incoming monomer which has a protected 3'-amino group. The resulting internucleotide phosphoramidite linkage is then oxidized to form a stable protected phosphoramidate linkage. The method of the invention greatly improves product yields and reduces reagent usage over currently available methods for synthesizing the above class of compound.Type: GrantFiled: June 14, 1996Date of Patent: October 20, 1998Assignee: Lynx Therapeutics, Inc.Inventors: Bernard L. Hirschbein, Karen L. Fearon, Sergei M. Gryaznov, Sarah N. McCurdy, Jeffery S. Nelson, Ronald G. Schultz
-
Patent number: 5342816Abstract: An imaging medium capable of being imaged to form a transparency comprises a substantially transparent support having a thickness of at least about 20 .mu.m, a color-forming layer superposed on the support and comprising a color-forming composition adapted to undergo a change of color upon increase in the temperature of the color-forming layer above a color-forming temperature for a color-forming time; and a bubble-suppressant layer superposed on the color-forming layer and having a thickness of at least about 10 .mu.m. Upon imagewise increase in the temperature of the color-forming layer above the color-forming temperature for the color-forming time, in heated regions the color-forming layer undergoes its change of color but remains essentially free from bubbles, thereby providing an image in which the colored regions are not blackened when viewed in transmission.Type: GrantFiled: August 18, 1993Date of Patent: August 30, 1994Assignee: Polaroid CorporationInventors: Edward P. Lindholm, Stephen J. Telfer, Michael J. Zuraw, Bernard L. Hirschbein
-
Patent number: 5292875Abstract: A method for synthesizing sulfurized oligonucleotide analogs, such as phosphorothioate and phosphorodithioate analogs, is provided that employs a thiophosphorus compound, such as a thiophosphoric, dithiophosphoric, thiophosphinic, or dithiophosphinic acid disulfide or polysulfide, as a sulfurizing agent. The method of the invention may be used to sulfurize any phosphorous(III)containing intermediate. Preferably, the method is practiced on a commercial DNA synthesizer using phosophoramidite and/or phosphorthioamidite intermediates.Type: GrantFiled: August 27, 1993Date of Patent: March 8, 1994Assignee: Lynx Therapeutics, Inc.Inventors: Wojciech J. Stec, Bogdan Uznanski, B. John Bergot, Bernard L. Hirschbein, Karen L. Fearson
-
Patent number: 5166387Abstract: A method for synthesizing sulfurized oligonucleotide analogs, such as phosphorothioate and phosphorodithioate analogs, is provided that employs a thiuram disulfide as a sulfurizing agent. The method of the invention may be used to sulfurize any phosphorous(III)-containing intermediate. Preferably, the method is practiced on a commercial DNA synthesizer using phosphoramidite and/or phosphorthioamidite intermediates.Type: GrantFiled: January 12, 1990Date of Patent: November 24, 1992Assignee: Applied Biosystems, Inc.Inventor: Bernard L. Hirschbein
-
Patent number: 5151510Abstract: A method for synthesizing sulfurized oligonucleotide analogs, such as phosphorothioate and phosphorodithioate analogs, is provided that employs a thiophosphorus compound, such as a thiophosphoric, dithiophosphoric, thiophosphinic, or dithiophosphinic acid disulfide or polysulfide, as a sulfurizing agent. The method of the invention may be used to sulfurize any phosphorous(III)-containing intermediate. Preferably, the method is practiced on a commercial DNA synthesizer using phosphoramidite and/or phosphorthioamidite intermediates.Type: GrantFiled: April 20, 1990Date of Patent: September 29, 1992Assignee: Applied Biosystems, Inc.Inventors: Wojciech J. Stec, Bogdan Uznanski, B. John Bergot, Bernard L. Hirschbein, Karen L. Fearon
-
Patent number: 4478762Abstract: The potassium salt of phosphoenolpyruvic acid (PEP-K), used as a phosphorylation agent particularly in enzymatic reactions, is prepared by a process which consists of two steps, namely the treatment of a halopyruvic acid with a trialkyl phosphite and the hydrolysis of the dialkyl phosphate of enolpyruvic acid thus formed in an aqueous medium and in the presence of potassium hydroxide.Type: GrantFiled: March 30, 1982Date of Patent: October 23, 1984Assignee: Massachusetts Institute of TechnologyInventors: George M. Whitesides, Bernard L. Hirschbein, Francois P. Mazenod